Comparing kidney dialysis patterns on calcium levels with citrate blood thinner
Part of Kidney & urinary clinical trials.
This study compares different patterns of continuous kidney dialysis (called CRRT) to see how they affect calcium levels in the blood when using a citrate-based blood thinner. It may help find the safest way to manage calcium during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently receiving citrate anticoagulation (a blood thinner used during dialysis).
- You are not pregnant or breastfeeding.
- You do not have a known allergy to citrate anticoagulants.
- You do not have severe liver problems (bilirubin more than twice normal).
- You do not have very low oxygen levels, very low blood pressure, high lactate levels, high sodium, or a hospital stay shorter than 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of dialysis (hemodialysis and hemodiafiltration) to see which is better at removing waste from the blood in ICU patients with sudden kidney failure. It may help doctors choose the best treatment for you.
This study tests a new way to give a blood thinner during dialysis to people whose bodies cannot break it down normally. It aims to make dialysis safer and more comfortable for people with kidney and liver problems.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This Phase 3 study checks whether Prismocitrate 18 is safe for adults who need a kidney filtration treatment called CRRT. It is mainly for people who cannot safely use heparin (a common blood thinner) due to bleeding risk.
This trial looks at whether a blood thinner called citrate is safe and effective in patients who have both kidney and liver failure while on continuous dialysis in the ICU. It may help guide treatment for people with serious organ problems.
This study tests a special blood-filtering treatment for patients in the intensive care unit (ICU) with acute kidney injury. It uses a medicine called citrate to prevent blood clotting during dialysis, which may be safer for patients whose liver cannot process citrate normally.
Hear when a new Renal Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.